Drug-resistant Trials

Trials for Gleevec, Sutent, Stivarga resistant GIST

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Phase I trials are included in this listing. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov. The drug name listed will be the most advanced available; i.e., brand name first or generic name and if neither of those are available, IND.

22 trials found

PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Phase:  1/2
Category:   KIT inhibitor + PD-1 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)
Phase:  1/2
Category:   KIT + Nuclear export inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Hospital Vall d'Hebron Barcelona Spain
Hospital Virgen del Rocio Sevilla Spain
 


A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Phase:  1/2
Category:   KIT Inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Memorial Sloan Kettering New York NY USA
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
Mayo Clinic, Jacksonville Jacksonville FL USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Fox Chase Cancer Center Philadelphia PA USA
 


(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase:  3
Category:   KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Mid Florida Hematology and Oncology Center Orange City FL USA
University of Toledo Medical Center Toledo OH USA
City of Hope Duarte CA USA
Medstar Hospital Washington Washington DC USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Orlando Health UF Health Cancer Center Orlando FL USA
University of Michigan Ann Arbor MI USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Fox Chase Cancer Center Philadelphia PA USA
 


Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Phase:  3
Category:   KIT/PDGFRA inhibitor + VEGF inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
PLA General Hospital Beijing China
 


A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)
Phase:  2
Category:   PD-L1 + KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Marie Sklodowska-Curie Memorial Cancer Center Warsaw Poland
 


Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)
Phase:  2
Category:   KIT/PDGFra/RET/FGFR/VEGFR inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Institut Paoli Calmette Marseilles France
Centre Léon Bérard Lyon Rhone France
 


Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Phase:  2
Category:   Tubulin inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Phase:  2
Category:   KIT/PDGFRA/VEGF inhibitors
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
 


Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase:  2
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA
 


A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
 


Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
Phase:  1/2
Category:   HDAC inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
Stanford University Medical Center Palo Alto CA USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
University of Michigan Ann Arbor MI USA
New York University New York NY USA
Mary Crowley Medical Research Center (Central Office) Dallas TX USA
McGill University Montreal QC Canada
Lombardi CCC at Georgetown University Washington DC USA
 


A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Phase:  1/2
Category:   Kit inhibitor + PD-L1 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Régional de Lutte contre le Cancer de Montpellier Montpellier Herault France
Institut Claudius Regaud Toulouse France
 


Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:   SDH-directed
Conditions:  Sarcoma

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
National Cancer Institute Bethesda MD USA
City of Hope Duarte CA USA
Memorial Sloan Kettering New York NY USA
Washington University School of Medicine St. Louis MO USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
University of Colorado Aurora CO USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
University of Michigan Ann Arbor MI USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
 


Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase:  1
Category:   Immune stimulate
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Ohio State University Comprehensive Cancer Center Columbus OH USA
 


A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Phase:  1
Category:   KIT inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Guangdong General Hospital Guangzhou Guangdong China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Chinese PLA General Hospital Beijing China
Fudan University Shanghai Cancer Center Shanghai China
 


Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase:  1
Category:   KIT/PDGFRA inhibitor + CTLA4 inhibitor
Conditions:  Advanced Cancer

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
 


Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase:  1
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
City of Hope Duarte CA USA
Sarcoma Oncology Center Santa Monica CA USA
University of Colorado Aurora CO USA
Emory Winship Cancer Institute Atlanta GA USA
University of Chicago Chicago IL USA
University of Michigan Ann Arbor MI USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Inova Health System Fairfax VA USA
Memorial Sloan Kettering New York NY USA
START Midwest Michigan, PC Grand Rapids MI USA
Virginia Cancer Specialists Fairfax VA USA
Valkyrie Clinical Trials INC Los Angeles CA USA
 


A Study of NB003 in Patients With Advanced Malignancies
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Memorial Sloan Kettering New York NY USA
Peking University School of Oncology Beijing China
Fudan University Shanghai Cancer Center Shanghai China
 


[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)
Phase:  1
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
City of Hope Duarte CA USA
Stanford Cancer Center Palo Alto CA USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Oregon Health & Science University Portland OR USA
Medizinische Universitat Innsbruk - Universitatklinil fur Nuklearmedizin Innsbruck Austria
Erasmus Medical center Rotterdam Netherlands
 


A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors
Phase:  1/2
Category:   PD-L1 inhibitor + TKI
Conditions:  Solid Tumors

Site
City
State
Country
Ashford Cancer Centre Research Kurrulta Park South Australia Australia
 


Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Phase:  2
Category:   TRK Inhibitor
Conditions:  Sarcoma

Site
City
State
Country
Stanford University Medical Center Palo Alto CA USA
Memorial Sloan Kettering New York NY USA
Fox Chase Cancer Center Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Samsung Medical Center Seoul Republic of Korea
Inova Health System Fairfax VA USA
Ronald Reagan UCLA Medical Center Los Angeles CA USA
Massachusetts General Hospital Boston MA USA
Dana Farber Cancer Institute Boston MA USA
Wake Forrest Winston-Salem NC USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
National Cancer Center Singapore Singapore
Hospital Vall d'Hebron Barcelona Spain
Medstar Hospital Washington Washington DC USA
Memorial Hospital Pembroke Pines FL USA
Thomas Jefferson University Philadelphia PA USA
West Virginia University Morgantown WV USA
Copenhagen University Hospital Copenhagen Denmark
St Vincent's University Hospital Dublin Ireland
Severance Hospital, Yonsei University Health System Seoul Republic of Korea
John Theurer Cancer Center at Hackensack Hackensack NJ USA
Avera Cancer Institute Sioux Falls SD USA
Fundacion Jimenez Diaz Madrid Spain
Institut Bergonie Bordeaux Gironde France
Seoul National University Hospital Seoul Republic of Korea
University College Hospital London UK
Roswell Park Cancer Institute Buffalo NY USA
University of Chicago Chicago IL USA
Barts Health NHS Trust Royal London London UK
University Hospital Southampton Southampton UK
Centro Integral Oncologico Clara Campal Madrid Spain
Instituto Purtugues de Oncologia do Porto Francisco Gentil Porto Portugal
University of North Carolina (UNC) Chapel Hill NC USA
National Cancer Center Hospital East Chiba Japan
Charite Comprehensive Cancer Center (CCCC) Berlin Germany
 


22 trials found